Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy - Takeaway - MDSpire
Feature

Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy

New Eveo system is designed to raise CAR-T output, cut manufacturing costs, and ease cleanroom bottlenecks

  • April 7, 2026

  • 2 min

Share

  • 1

    Sartorius has launched the Eveo Cell Therapy Platform for CAR-T therapies.

  • 2

    The platform enhances manufacturing efficiency and reduces costs.

  • 3

    Enables processing of eight patient batches simultaneously.

  • 4

    Anticipated production cost reduction by 90%.

  • 5

    Orders start in September 2026 with deliveries expected in

  • 6

    ElevateBio is a preferred partner for early access.

Original Source(s)

Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy

  • April 7, 2026

Related Content

Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

Oncology trials account for a substantial proportion of impacted activity, with non–small cell lung cancer representing the most affected indication, followed by breast cancer.

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approac...